Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women

Gerbaldo, Daniela; Ferraiolo, Antonella; Croce, S.; Truini, Mauro; Capitanio, G. L.

doi:10.1016/0378-5122(91)90235-i

Cited by 30 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18<25 Importantly, in most studies, estriol has been demonstrated to be safe in terms of endometrial proliferation. 18,24,26,27 The present trial is based on the results obtained in a preliminary study carried out in healthy postmenopausal volunteers, where the pharmacokinetics and preliminary safety and efficacy of a new 0.005% estriol vaginal gel delivering 50 Kg of estriol per application were studied and compared with those of the reference marketed product (vaginal cream delivering 0.5 mg of estriol per application) and with placebo. Although demonstrating efficacy, the new gel revealed a very favorable safety profile, showing almost negligible plasma levels of estriol after daily administration over 21 days, significantly lower than those produced by the reference product.…”

mentioning

confidence: 99%

The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy

et al. 2012

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…We have chosen to use oestriol since it is a weak, naturally occurring oestrogen metabolite that is normally present in human male urine, and it is unlikely to cause hypothalamic inhibition or gynecomastia. Similar treatment regimens in women [14] had no effect on circulating LH concentrations. A similar keratinisation response was detected in the vaginal epithelium of Rhesus monkeys using as little as 25 µg of oestriol applied twice weekly [13].…”

Section: Discussionmentioning

confidence: 90%

Topical Oestrogen Keratinises The Human Foreskin and May Help Prevent HIV Infection

Pask

McInnes²,

Webb

et al. 2008

PLoS ONE

View full text Add to dashboard Cite

With the growing incidence of HIV, there is a desperate need to develop simple, cheap and effective new ways of preventing HIV infection. Male circumcision reduces the risk of infection by about 60%, probably because of the removal of the Langerhans cells which are abundant in the inner foreskin and are the primary route by which HIV enters the penis. Langerhans cells form a vital part of the body's natural defence against HIV and only cause infection when they are exposed to high levels of HIV virions. Rather than removing this natural defence mechanism by circumcision, it may be better to enhance it by thickening the layer of keratin overlying the Langerhans cells, thereby reducing the viral load to which they are exposed. We have investigated the ability of topically administered oestrogen to induce keratinization of the epithelium of the inner foreskin. Histochemically, the whole of the foreskin is richly supplied with oestrogen receptors. The epithelium of the inner foreskin, like the vagina, responds within 24 hours to the topical administration of oestriol by keratinization, and the response persists for at least 5 days after the cessation of the treatment. Oestriol, a cheap, readily available natural oestrogen metabolite, rapidly keratinizes the inner foreskin, the site of HIV entry into the penis. This thickening of the overlying protective layer of keratin should reduce the exposure of the underlying Langerhans cells to HIV virions. This simple treatment could become an adjunct or alternative to surgical circumcision for reducing the incidence of HIV infection in men.

show abstract

“…the speed of absorption, conjugation and secretion, and on rapid dissociation of nuclear receptors. 35,36 Endometrial atrophy prior to treatment had not been assessed by other authors and, in the case of one study, only the results from the progesterone test were taken into consideration. 37 In a long-term study, Boseli et al evaluated the endometrium 3, 6, 12, 18 and 24 months after a vaginal estriol preparation in 0.5 mg doses had been applied, and they observed no proliferative changes.…”

Section: Discussionmentioning

confidence: 99%

xpression of estrogen and progesterone receptor genes in endometrium, myometrium and vagina of postmenopausal women treated with estriol

et al. 2009

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Estriol is an estrogen with considerably weaker stimulatory effects on endometrial proliferation than estradiol. A study was conducted to determine the level of estrogen receptors (ERs) and progesterone receptors (PRs) in women who received 14-day vaginal estriol therapy, compared with those who did not receive this therapy. ER and PR gene expression was analyzed in the endometrium, myometrium and vagina of postmenopausal women treated with estriol. DESIGN AND SETTING: Analytical cross-sectional study, at the Research Institute of the Polish Mothers' Memorial Hospital, Lodz, Poland. METHODS: Twenty-seven postmenopausal women (57-74 years of age) were included in the study. All of them were waiting for per vaginam hysterectomy or plastic surgery on the vagina and perineum because of uterine prolapse. ER and PR gene expression was determined by means of the technique of reverse transcription polymerase chain reaction (RT-PCR). RESULTS: In the estriol-treated patients, in comparison with the control group, a significant increase in ER gene expression was observed in the endometrium and vagina, while enhanced PR gene expression was found in the endometrium. However, under histological examination of the endometrium, estrogen stimulation of low and medium degree was diagnosed for 21.4% and 14.3% of the estriol-treated women, respectively. CONCLUSION: The results obtained suggest that the women who received 14 days of treatment with vaginal estriol had higher ER and PR mRNA levels. No difference between these groups regarding endometrial proliferation was observed.

show abstract

Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women

Cited by 30 publications

References 14 publications

The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy

The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy

Topical Oestrogen Keratinises The Human Foreskin and May Help Prevent HIV Infection

xpression of estrogen and progesterone receptor genes in endometrium, myometrium and vagina of postmenopausal women treated with estriol

Contact Info

Product

Resources

About